TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05171699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: The patients in Group EA received electroacupuncture at Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: shame electroacupuncture
Description: The patients in Group SEA received electroacupuncture at a shallow depth and 1 mm lateral to Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
Study: NCT05675345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC + CNEP20
Description: HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC + CNEP30
Description: HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
Study: NCT06245785

Intervention type: PROCEDURE
Intervention: transarterial chemoembolisation
Description: Before TACE, hepatic arteriography was performed to evaluate the vascular anatomy and tumour vascularity. During TACE, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function. Laboratory assessments were performed every four to six weeks. Radiological evaluation using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was recommended during weeks 4 and 8 after treatment and every 8 weeks thereafter. However, in clinical practice, the intensity of follow-up depends on an individual's baseline characteristics and response to the last treatment.
Study: NCT05512494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (Split Virion), inactivated
Description: The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (Split Virion), inactivated
Description: The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (Split Virion), inactivated
Description: The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
Study: NCT05540236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham auricular acupressure
Description: The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
Study: NCT05127343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sealing deep pits and fissures
Description: Application of the pit and fissure sealant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sealing deep pits and fissures
Description: Application of the pit and fissure sealant
Study: NCT06114420

Intervention type: PROCEDURE
Intervention: salvage surgery
Description: Some patients who cannot undergo surgery
Study: NCT04890002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far-infrared emitting pyjamas
Description: Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-pyjamas
Description: The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
Study: NCT04729803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Attention Guidance + Exposure
Description: 1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Exposure Alone
Description: 1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Attention Control + Exposure
Description: 1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~   F~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response.
Study: NCT06534281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BAO-G
Description: Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
Study: NCT04826744

Intervention type: OTHER
Intervention: Standard dermatology consultation
Description: with clinical examination, score filling such as SCORAD and DLQI~* Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~* Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~* ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)
Study: NCT04893993

Intervention type: DRUG
Group type: OTHER
Intervention: Thiamine
Description: Tablets. 300mg/tablet. Dosage depends on gender and weight

Intervention type: DRUG
Group type: OTHER
Intervention: Thiamine
Description: Tablets. 300mg/tablet. Dosage depends on gender and weight

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets. Same number of tablets as Thiamine

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets. Same number of tablets as Thiamine
Study: NCT05990309

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy
Description: skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy
Description: skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
Study: NCT05615753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
Study: NCT06194786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group D
Description: Usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group D
Description: Usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group D
Description: Usual care
Study: NCT06138522

Intervention type: BEHAVIORAL
Intervention: Semi-structured interviews
Description: Semi-structured interviews

Intervention type: BEHAVIORAL
Intervention: Semi-structured interviews
Description: Semi-structured interviews

Intervention type: BEHAVIORAL
Intervention: Child Post-Traumatic Stress Response Index (CPTS-RI) scale
Description: Child Post-Traumatic Stress Response Index (CPTS-RI) scale

Intervention type: BEHAVIORAL
Intervention: - Therapeutic Alliance Questionnaire (HAQ-CP)
Description: - Therapeutic Alliance Questionnaire (HAQ-CP)

Intervention type: BEHAVIORAL
Intervention: - Therapeutic Alliance Questionnaire (HAQ-CP)
Description: - Therapeutic Alliance Questionnaire (HAQ-CP)

Intervention type: BEHAVIORAL
Intervention: - Therapeutic Alliance Questionnaire (HAQ-CP)
Description: - Therapeutic Alliance Questionnaire (HAQ-CP)
Study: NCT06529666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didatic Session 1: Core Foundation Course
Description: A 45-minute foundational presentation covering key Weight Management Counseling (WMC) concepts, obesity bias, and cultural humility facilitated by a trained clinician-educator at the residency program delivered at baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The 3Ps Program
Description: 6 email modules delivered over months 2-8). Each 3P module will allow the resident to:~(1) Prepare: Review relevant concepts and demonstration videos sent via an email to prepare for completing the VCA vignettes; (2) Practice: Respond to brief vignettes of various 5As WMC challenging scenarios by audio recording their spoken response on the VCA tool; and (3) Process: Reflect on actionable expert and crowdsourced analogue patient feedback on the quality of their responses to each VCA vignette.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic session 2
Description: (months 8-10): This 45-minute session will discuss key barriers to WMC adoption in clinical practice using real-world cases captured from residents facilitated by a trained clinician-educator at the residency program.
Study: NCT06021834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: The subjects will be invited to attend the program three times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: The subjects will be invited to attend the program three times per week.
Study: NCT06529666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email reinforcement
Description: 2 emails in months 10-12 covering key concepts in the preceding components.
Study: NCT05356351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48- ADC
Description: RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
Study: NCT06529666

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PowerPoint of the foundational course
Description: Residents will receive a core foundation slides on weight management counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PowerPoint of the foundational course
Description: Residents will receive a core foundation slides on weight management counselling
Study: NCT05440578

Intervention type: DRUG
Intervention: olaparib plus bevacizumab maintenance therapy
Description: First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
Study: NCT05275777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as an intravenous infusion.
Study: NCT06403566

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand massage
Description: three group randomized controlled trials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage
Description: three group randomized controlled trials
Study: NCT05575947

Intervention type: DEVICE
Intervention: da Vinci Surgical System
Description: da Vinci Surgical System

Intervention type: PROCEDURE
Intervention: laparoscopic bariatric surgery
Description: laparoscopic bariatric surgery
Study: NCT04938609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (5 days)
Description: 8Gy x 3 (Mon-Fri) GTV+3mm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor
Study: NCT05839860

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Salt 3 g
Description: Placebo group taking a breakfast meal and 3g salt on tomatoes before fasting for 7 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salt 6 g
Description: Intervention group taking a breakfast meal and 6g salt on tomatoes plus 1 L water before fasting for 7 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salt 9 g
Description: Intervention group taking a breakfast meal and 9g salt on tomatoes plus 1 L water before fasting for 7 hours
Study: NCT04860726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint mobilization
Description: Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes
Study: NCT05183997

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: complete blood count
Description: laboratory test
Study: NCT04860726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min ii. heating pad for 15 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint mobilization & Myofascial Release
Description: Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes iv. Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min
Study: NCT05043337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal voice
Description: The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture.
Study: NCT05183997

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: complete blood count
Description: laboratory test

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: prothrombin time
Description: laboratory test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: prothrombin time
Description: laboratory test

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: prothrombin concentration
Description: laboratory test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: prothrombin concentration
Description: laboratory test
Study: NCT06334250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation using Pulsed Field Ablation
Description: Pulsed Field Ablation of atrial fibrillation at the time of left atrial appendage occlusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion
Description: Left atrial appendage occlusion using the Watchman device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage occlusion
Description: Left atrial appendage occlusion using the Watchman device
Study: NCT05973188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Anticoagulant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: Anticoagulant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5mg or 2.5mg oral tablet
Description: Anticoagulant
Study: NCT05457023

Intervention type: OTHER
Intervention: Plasma Neurofilament Light (NF-L)
Description: Plasma NF-L is a biomarker of axonal brain injury following sports-related head impacts.

Intervention type: OTHER
Intervention: Omega-3 Index
Description: Omega-3 Index is the omega-3 fatty acid content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) within the erythrocyte cell membrane. It is expressed as EPA+DHA as a percent of total identified fatty acids.

Intervention type: OTHER
Intervention: HeadCount Questionnaire
Description: HeadCount is a web-based, structured, self-administered questionnaire to assess longer-term heading exposure during competitive play and is administered bi-weekly.
Study: NCT05043337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lullaby
Description: The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal voice combined with lullaby
Description: The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.